DNA methylation

Overview

DNA methylation is a fundamental epigenetic modification in which a methyl group (–CH₃) is covalently added to the fifth carbon of cytosine residues, primarily at cytosine-phosphate-guanine (CpG) dinucleotides, through the enzymatic action of DNA methyltransferases (DNMTs). This reversible chemical modification does not alter the underlying nucleotide sequence but profoundly influences gene expression by modulating chromatin accessibility and the binding of transcriptional regulators. Hypermethylation of gene promoter regions is canonically associated with transcriptional silencing, while hypomethylation is associated with gene activation — a balance that is critical for normal development, tissue differentiation, and cellular homeostasis.

As one of the most extensively studied epigenetic mechanisms, DNA methylation serves as a molecular interface between the genome and the environment, translating external signals — including diet, toxin exposure, lifestyle, and aging — into durable changes in gene regulatory programs. It operates in concert with complementary epigenetic processes such as histone modification and chromatin remodeling, and its aberrant patterning underlies a broad spectrum of human diseases, most notably cancer, metabolic disorders, neurocognitive conditions, and cardiovascular disease. The reversibility of DNA methylation marks makes DNMTs and their regulatory networks attractive targets for pharmacological intervention, driving a rapidly expanding field of epigenome-targeted therapeutics.

Focus of Latest Publications

Cancer Biology and Oncogenesis

DNA methylation dysregulation has emerged as a central mechanistic driver across multiple cancer types. In pancreatic cancer, a 2026 narrative review (PMID: 41879036) examined how aberrant DNA methylation patterns contribute to tumorigenesis, highlighting both mechanistic roles and translational applications in biomarker development and therapy. Similarly, thyroid cancer research has shown that aberrant DNMT activity causes pathological hypomethylation: sustained inhibition of DNMT1 was found to trigger apoptosis in thyroid cancer cells (PMID: 42048599), including both papillary thyroid cancer and follicular thyroid cancer subtypes, suggesting that pharmacological induction of DNA hypomethylation could serve as a therapeutic strategy.

In colon cancer, detection of methylation changes in clinical settings has driven biosensor innovation, though traditional assays have historically faced challenges in sensitivity, specificity, and cost-efficiency (PMID: 41643420). For hepatocellular carcinoma (liver cancer), machine learning-based multi-omics analyses identified genes — including EZH2, CEP55, and DLGAP5 — exhibiting aberrant DNA methylation patterns strongly associated with advanced disease stage and resistance to immunotherapy (PMID: 41984188). EZH2, a histone methyltransferase, is itself an epigenetic regulator, underscoring the cross-talk between DNA methylation and histone modification in oncogenic programs.

In melanoma, IDH gain-of-function (GOF) mutations were shown to disrupt global DNA methylation patterns, leading to tumor-infiltrating lymphocyte exclusion and poor response to checkpoint inhibitor therapy, including checkpoint inhibitor regimens (PMID: 41955022). This finding positions DNA methylation as a mediator of immune evasion, directly implicating it in T-cell receptor-mediated antitumor immunity. In renal cell carcinoma, promoter methylation of STING1 was investigated as a mechanism of immune suppression, with studies revealing correlations between methylation patterns and immune cell infiltration (PMID: 41942521). STING1 is a central innate immune sensor, and its silencing via methylation may limit the tumor's immunogenicity, hampering responses to proinflammatory cytokine signaling cascades.

In triple-negative breast cancer (TNBC), epigenetic regulation via DNA methylation was found to govern the expression of NY-ESO-1, a cancer-testis antigen recognized by T-cell receptors and antibodies, raising interest in demethylation strategies to enhance immunotherapy efficacy (PMID: 41846058). Across cancer types, a pan-cancer classification framework built on DNA methylation data demonstrated the feasibility of using methylation biomarkers for multi-cancer tracing and diagnosis (PMID: 42152108), with a tissue-specific methylation and expression database (TiSMeD) further cataloguing over 67,000 high-confidence tissue-specific methylation sites to support translational applications (PMID: 41883585).

Metabolic and Endocrine Disease

In the context of type 2 diabetes, Mendelian randomisation analysis in West African populations investigated the causal relationship between specific CpG methylation sites and glycaemic traits (PMID: 42032377), acknowledging that evidence for causality has historically been limited by the cross-sectional nature of epigenome-wide association studies. A complementary multi-omics genetic study (PMID: 42163256) demonstrated that DNA methylation mediates the anti-aging effects of glucose-lowering drugs, suggesting that methylation reprogramming is a mechanistic pathway through which these agents extend metabolic healthspan.

Childhood obesity research identified DNA methylation as a key molecular interface between environmental inputs — including obesity and maternal pre- or early-pregnancy obesity — and changes in gene expression during development (PMID: 42116681). Nutritional status was highlighted as a modifiable determinant of methylation patterning, positioning epigenetic interventions as potential preventive targets in pediatric metabolic disease.

Aging and Environmental Exposures

DNA methylation-based epigenetic clocks (e.g., GrimAge and DunedinPACE) have become powerful tools for quantifying biological aging. A longitudinal cohort study in older Asian adults examined the associations between 15 modifiable lifestyle factors and DNAm clock acceleration (PMID: 41763011), reinforcing the view that methylation dynamically records cumulative environmental and behavioral exposures. In skin biology, epigenetic clocks revealed that DNA methylation plays a pivotal role in regulating gene expression and tissue function in a tissue highly responsive to environmental stressors (PMID: 41957838).

Environmental toxicant exposure was explored in a study demonstrating that short-term PM 2.5 exposure impairs cognitive function, with DNA methylation of circadian rhythm genes identified as a mediating mechanism in middle-aged and older adults (PMID: 41979129). Age-varying methylation patterns were also associated with Blood Pressure across mid-to-late adulthood (PMID: 42092955), illustrating how methylation relationships with cardiovascular phenotypes shift dynamically over the life course.

Cardiovascular and Neurological Disease

Epigenetic mechanisms encompassing DNA methylation, histone modifications, and non-coding RNAs were described as fundamentally involved in the initiation and progression of cardiovascular diseases, with traditional Chinese medicine proposed as a multi-target strategy for rewiring the cardiovascular epigenome (PMID: 41906543). In perioperative neurocognitive disorders, DNA methylation was identified as linking genetic susceptibility with environmental exposures and perioperative stressors, modulating immune activation and neurotransmission (PMID: 41620312).

Infectious Disease and Multi-Omics Integration

In the context of latent cytomegalovirus infection among people living with HIV, a five-layer multi-omics study included DNA methylation as a key molecular signature alongside genomics, transcriptomics, plasma proteins, and Metabolites (PMID: 41881997). In smoking-induced COPD, epigenomic analyses incorporating DNA methylation data alongside acetylomic and proteomic datasets revealed patterns of chronic inflammation and steroid resistance (PMID: 41605376). The integration of DNA methylation with mRNA expression was also central to cancer survival prediction models, with studies noting that the two layers are tightly coupled regulatory components whose nonlinear cross-omics structure is best captured by deep learning approaches (PMID: 41973703). However, the reliability of methylation data in tumor microbiome studies was found to be limited, with concordance between host-microbe associations nearly absent for methylation and protein data relative to gene expression (PMID: 42017663), underscoring the need for context-dependent data quality evaluation.

Key Publications

• May The tissue-specific effects of glucose-lowering drug targets on aging mediated through DNA methylation: a multi-omics genetic study. (BMC medicine, 2026, PMID 42163256): "DNA methylation plays a key role in mediating the anti-aging effects of glucose-lowering drugs."
• May Systematic evaluation of TCGA tumor microbiota reveals context-dependent reliability. (mSystems, 2026, PMID 42017663): "The concordance of downstream host-microbe associations was moderate for gene expression but nearly absent for methylation and protein data."
• May DNA methylation biomarkers-based pan-cancer classifier: predictive modeling for cancer classification. (Genome medicine, 2026, PMID 42152108): "Here, we aimed to develop and validate a pan-cancer classification framework based on DNA methylation data, that addresses methodological challenges of omics data powered ML."
• May Active-site rich nanostructure with dual-enhanced electron transfer for ultra-sensitive electrochemiluminescence detection of DNA methylation in colon cancer. (Biosensors & bioelectronics, 2026, PMID 41643420): "Traditional DNA methylation assays for colon cancer still face challenges of insufficient sensitivity, limited specificity, and low cost-efficiency in clinical samples."
• May Epigenetics and Childhood Obesity: DNA Methylation Coordinates Environment and Gene Regulation. (Endocrine reviews, 2026, PMID 42116681): "Of them, DNA methylation has emerged as an important molecular interface between environmental inputs and changes in gene expression."
• May Age-varying DNA methylation patterns associated with blood pressure in mid-to-late adulthood. (Clinical epigenetics, 2026, PMID 42092955): "Epigenome-wide association studies (EWAS) have identified associations between DNA methylation and blood pressure, yet most rely on single-time-point data and cannot capture how methylation and blood pressure relationships change with age."
• May Multilevel exposure to adversity across the life course and biological implications among urban postpartum women: A cohort study protocol. (PloS one, 2026, PMID 42090372): "To identify the biological pathways of adversity, we employ multi-omics profiling of peripheral blood mononuclear cells-including DNA methylation, chromatin accessibility, and histone modification-alongside inflammatory and steroid hormone assays."
• May Sustained DNA Hypomethylation Induced by a DNA Methyltransferase 1 Inhibitor Triggers Apoptosis in Thyroid Cancer Cells. (Drug development research, 2026, PMID 42048599): "DNA methylation, is catalyzed by DNA methyltransferases (DNMTs), and its aberrant patterns are implicated in thyroid cancer pathogenesis."
• Apr Causal relationship between epigenetic markers and type 2 diabetes in West African populations: a Mendelian randomisation analysis. (Diabetologia, 2026, PMID 42032377): "Evidence for a causal role of DNA methylation sites (CpGs) in type 2 diabetes and glycaemic traits is limited due to the cross-sectional nature of many epigenome-wide association studies (EWAS)."
• Apr Machine learning-based multi-omic analysis identifies CEP55, DLGAP5, and EZH2 as regulated cell death biomarkers linked to immunotherapy resistance in hepatocellular carcinoma. (Naunyn-Schmiedeberg's archives of pharmacology, 2026, PMID 41984188): "These genes were significantly overexpressed in tumors, associated with advanced stage and poor differentiation, and showed aberrant DNA methylation."